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Renal function and early 
revascularization in non-ST-
elevation myocardial infarction
Szummer et al., Circulation advance online publication, 24 August 2009, 
doi:10.1161/CIRCULATIONAHA.108.838169 
Shorter time from presentation with chest pain to revasculariza-
tion in myocardial infarction associated with ST elevation results in 
with lower mortality,1 all-cause mortality, and nonfatal myocardial 
infarction.2 A new analysis evaluated the association between early 
revascularization and similar outcomes among 23,262 consecutive 
non-ST-elevation myocardial infarction patients stratified by renal 
function. Patient data were taken from the Swedish Web-System 
for Enhancement and Development of Evidence-Based Care in 
Heart Disease Evaluated According to Recommended Therapies 
(SWEDEHEART). Early revascularization was defined as having 
a procedure within 14 days of admission. Patients with declining 
kidney function experienced a gradually lesser degree of beneficial 
association between early revascularization and mortality at 1 year. 
Among patients with an estimated glomerular filtration rate (eGFR) 
higher than 90 ml/min, early revascularization was associated with 
a hazard ratio (HR) of 0.58 (P = 0.001). The HR for mortality rose 
gradually toward 1.0 among patients with worse kidney function. 
Among patients with an eGFR of 60–89 ml/min, 30–59 ml/min, 
and 15–29 ml/min and patients with an eGFR less than 15 ml/min 
or on dialysis, the HRs for mortality were 0.64 (P < 0.001), 0.68 
(P = 0.001), 0.91 (P = 0.740), and 1.61 (P = 0.150), respectively. 
The authors conclude that the beneficial association between early 
invasive therapy and greater 1-year survival in patients with non-
ST-elevation myocardial infarction declines among patients with 
greater renal insufficiency.
Although the cohort included a large group of patients, the small 
sample size of those with advanced kidney disease (approximately 
850 of them) gives the results limited power. Further, factors such as 
accelerated atherosclerosis, increased vascular calcification, and the 
higher risk of sudden death make the epidemiology of cardiovascular 
disease among patients with kidney disease arguably different from 
that among patients without heart disease. This different pathobiology 
of heart disease in kidney disease patients may cause therapies such 
as early revascularization to be less effective, as we have seen in the 
use of statins among patients with kidney disease.3,4
Lynda Szczech
1J Am Coll Cardiol 2006; 47: 289–295. 2J Am Coll Cardiol 2006; 48: 1319–1325. 
3N Engl J Med 2005; 353: 238–248. 4N Engl J Med 2009; 360: 1395–1407.
The (pro)renin receptor  
and the renal H+-ATPase
Advani et al., Hypertension 2009; 54: 261–269; doi:10.1161/
HYPERTENSIONAHA.109.128645
The transmembrane protein that binds renin and prorenin—the 
(pro)renin receptor ((P)RR)—has attracted considerable interest. 
But despite much work, its exact function in the regulation of the 
cardiovascular and renal actions of the renin–angiotensin system 
remains to be defined. Ligand binding to the (P)RR increased the 
enzymatic activity of renin and stimulated intracellular signaling, 
with activation of mitogen-activated protein kinases and induction 
of transforming growth factor-β expression. The (P)RR was initially 
located in the mesangium and was believed to be a novel protein. 
However, more recent work indicated that it is expressed in nearly 
all cells of the body, with particular abundance in the central nervous 
system. Interestingly, the (P)RR is also found in animals that do not 
have a renin–angiotensin system, such as C. elegans and Drosophila. 
It has also been recognized that the (P)RR is identical to a protein 
(ATP6AP2) originally described as being associated with the vacu-
olar hydrogen adenosine triphosphate (H+-ATPase) in chromaffin 
cells of the adrenal medulla. Needless to say, the vacuolar H+-ATPase 
acidifies intracellular vesicles (such as lysosomes and endosomes), 
synaptic vesicles, and also the urine. Interestingly, in the kidney, (P)
RR/ATP6AP2 has recently been located in distal parts of the nephron. 
Thus, Advani et al. postulated that the (P)RR may be involved in regu-
lating the vacuolar H+-ATPase in the kidney, and thereby renal acidi-
fication. Using a variety of methods, they found that (P)RR mRNA 
and protein were predominantly expressed in collecting ducts and 
in the distal nephron. Within collecting ducts, the (P)RR was most 
abundant in microvilli at the apical surface of A-type intercalated 
cells, where it colocalizes with a subunit of the vacuolar H+-ATPase 
(Figure). In vitro experiments suggested that inhibition of vacuolar 
H+-ATPase prevented (P)RR/ATP6AP2 intracellular signaling. These 
results cast new light on recent reports indicating that angiotensin 
activates H+-ATPase in collecting duct intercalated cells.
Juan Oliver 
The Ca-sensing receptor  
promotes urinary acidification  
to prevent nephrolithiasis
Renkema et al., J Am Soc Nephrol 2009; 20: 1705–1713; doi:10.1681/
ASN.2008111195
Disturbed intestinal calcium (Ca)2+ hyperabsorption, impaired 
renal Ca2+ reabsorption, and increased bone resorption are the 
Dual-staining immunofluorescence in rat kidney collecting ducts for 
the (pro) renin receptor (a and d, red) and the B1/2 subunit of the 
vacuolar H+-ATPase (b and e, green); (c and f) merge. 
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three causes of hypercalciuria, the main risk factor for the devel-
opment of nephrocalcinosis/nephrolithiasis. In the case of Ca 
stones, supersaturation is driven by urine Ca concentration, a 
function of Ca excretion and urine volume. For CaP, supersatu-
ration is also controlled by urine pH, because solubility of this 
salt decreases as urine pH rises; CaP stones are seen largely in 
patients with urine pH greater than 6. Renkema et al. now pro-
vide evidence that the magnitude of urinary supersaturation 
produced by hypercalciuria may be partially offset by effects 
of luminal Ca concentration on water reabsorption and urine 
pH, mediated through the collecting duct apical cell membrane 
Ca-sensing receptor (CaSR). They used mice in which the distal 
tubule Ca channel (TRPV5) was eliminated (TRPV5–/–); these 
mice have hypercalciuria and also exhibit polyuria and higher 
acidic urine pH than their wild-type littermates.1 Expression of 
renal aquaporin-2 (AQP2) is downregulated in TRPV5–/– mice 
compared with controls, a finding consistent with the work of 
others showing that stimulation of the apical CaSR decreased 
insertion of AQP2 into collecting duct apical membranes and 
impaired vasopressin-stimulated water reabsorption.2 In addi-
tion, urine net acid excretion was higher and urine pH was lower 
in the TRPV5–/– mice than in controls. Exposure of dissected 
mouse outer medullary collecting ducts to high (5.0 mM) extra-
cellular Ca2+ stimulated H+-ATPase activity. In TRPV5–/– mice, 
activation of the renal CaSR promoted H+-ATPase-mediated H+ 
excretion and downregulation of AQP2, leading to urinary acid-
ification and polyuria, respectively. Gene ablation of the collect-
ing duct−specific B1 subunit of H+-ATPase in TRPV5–/– mice 
abolished the enhanced urinary acidification, which resulted 
in severe tubular precipitations of Ca2+-phosphate in the renal 
medulla. Activation of CaSR by increased luminal Ca2+ led to 
urinary acidification and polyuria. These beneficial adaptations 
facilitate the excretion of large amounts of soluble Ca that is 
crucial to preventing the formation of kidney stones.
These convincing data may have limited application to 
humans with hypercalciuria, since the urine Ca concentra-
tions in TRPV5–/– mice are many times higher than the urine 
Ca concentrations in human stone formers. Hence, the stimu-
latory effect of these relatively low ionized Ca concentrations 
will have only a weak effect on the CaSR in the nephron.
Marc De Broe
1J Clin Invest 2003; 112: 1906–1914. 2J Am Soc Nephrol 2008; 19: 109–116.
Intracellular activation  
of vasopressin V2 receptor  
by nonpeptide agonists
Robben et al., Proc Natl Acad Sci USA 2009; 106: 12195–12200; doi:10.1073/
pnas.0900130106
In the collecting duct, vasopressin acts upon binding to the vaso-
pressin type 2 receptor (V2R) located in the principal cells; patients 
with V2R gene mutations may suffer from congenital nephrogenic 
diabetes insipidus (NDI). In cell-culture studies, nearly all missense 
V2R mutants in congenital NDI appear misfolded, endoplasmic 
reticulum−retained, and unstable. However, some of these V2R 
mutants appear intrinsically functional, because they exert a 
vasopressin-induced cyclic adenosine monophosphate response 
when, because of overexpression, they are expressed in the plasma 
membrane. This action suggests that the inability of intracellularly 
retained V2R mutants to escape the endoplasmic reticulum quality 
control and traffic to the basolateral membrane is fundamental to 
the disease. V2R is a G protein−coupled receptor and, like many 
of these receptors, is thought to function only when expressed in 
the plasma membrane. Thus, work toward treatment of congenital 
NDI has focused on nonpeptide receptor antagonists, which may 
interact with and stabilize endoplasmic reticulum-retained V2R 
mutants to rescue their cell-surface expression. Once there, they 
could be activated by high concentrations of 1-desamino-[d-Arg8]-
vasopressin (dDAVP), which would displace the bound antagonist. 
Interestingly, the pharmaceutical industry has recently developed 
nonpeptide V2R-specific agonists, because these drugs can be orally 
administered to treat incontinence and bed-wetting. Since with oral 
administration these drugs have to pass the intestinal cell layer, Rob-
ben et al. reasoned that they must be able to pass cell membranes, 
and thus may facilitate the transport of V2R mutants in congenital 
NDI to the cell surface, where they could directly activate the mutant 
receptors. The authors found that nonpeptide V2R agonists, but not 
vasopressin, activated NDI-causing V2R mutants at their intracel-
lular location without changing their maturation. More importantly, 
the agonists were capable of activating the intracellular V2R mutants 
so that translocation of AQP2 to the apical membrane took place 
(Figure). In addition, in contrast to plasma membrane V2R, deg-
radation of intracellular V2R mutants was not increased by their 
activation. These intriguing results indicate that G protein−coupled 
receptors normally active at the plasma membrane can be activated 
intracellularly, and that intracellular activation does not induce their 
degradation. Thus, nonpeptide agonists constitute highly promising 
therapeutics for diseases caused by misfolded G protein−coupled 
receptors in general, and congenital NDI in particular.
Juan Oliver
Agonist-induced translocation of AQP2 to the plasma membrane.
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